Bedaquiline Resistance after Effective Treatment of Multidrug-Resistant Tuberculosis, Namibia
Bedaquiline is currently a key drug for treating multidrug-resistant or rifampin-resistant tuberculosis. We report and discuss the unusual development of resistance to bedaquiline in a teenager in Namibia, despite an optimal background regimen and adherence. The report highlights the risk for bedaq...
Main Authors: | Gunar Günther, Lusia Mhuulu, Azaria Diergaardt, Viola Dreyer, Maria Moses, Kaarna Anyolo, Nunurai Ruswa, Mareli Claassens, Stefan Niemann, Emmanuel Nepolo |
---|---|
Format: | Article |
Language: | English |
Published: |
Centers for Disease Control and Prevention
2024-03-01
|
Series: | Emerging Infectious Diseases |
Subjects: | |
Online Access: | https://wwwnc.cdc.gov/eid/article/30/3/24-0134_article |
Similar Items
-
Therapeutic Failure and Acquired Bedaquiline and Delamanid Resistance in Treatment of Drug-Resistant TB
by: James Millard, et al.
Published: (2023-05-01) -
Revised Definitions of Tuberculosis Resistance and Treatment Outcomes, France, 2006–2019
by: Yousra Kherabi, et al.
Published: (2022-09-01) -
Advances of new drugs bedaquiline and delamanid in the treatment of multi-drug resistant tuberculosis in children
by: Hanzhao Zhu, et al.
Published: (2023-06-01) -
Implementation of targeted next-generation sequencing for the diagnosis of drug-resistant tuberculosis in low-resource settings: a programmatic model, challenges, and initial outcomes
by: Leonardo de Araujo, et al.
Published: (2023-08-01) -
New drugs in the treatment of drug-resistant tuberculosis in children. Experience with the use of delamanid in combination with bedaquiline
by: Ekaterina Sokolskaya, et al.
Published: (2024-12-01)